Eyal C. Attar Vor Biopharma Inc. (VOR) insider trading activity

Eyal C. Attar is CHIEF MEDICAL OFFICER of Vor Biopharma Inc.. Currently has a direct ownership of 126,625 shares of VOR, which is worth approximately $173,476. The most recent transaction as insider was on Feb 13, 2025, when has been sold 2,227 shares (Common Stock) at a price of $1.42 per share, resulting in proceeds of $3,162. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 127K

37.98% 3M change

12.2% 12M change

Total Value Held $173,476

Eyal C. Attar Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 13 2025	SELL Open market or private sale	$3,162 $1.42 p/Share	2,227 Reduced 1.73%	126,625 Common Stock
Feb 10 2025	SELL Open market or private sale	$3,498 $1.37 p/Share	2,554 Reduced 1.94%	128,852 Common Stock
Feb 06 2025	SELL Payment of exercise price or tax liability	$1,770 $1.5 p/Share	1,180 Reduced 0.89%	131,406 Common Stock
Feb 03 2025	SELL Payment of exercise price or tax liability	$1,813 $1.34 p/Share	1,353 Reduced 1.66%	80,086 Common Stock
Feb 03 2025	BUY Grant, award, or other acquisition	-	52,500 Added 28.37%	132,586 Common Stock
Dec 27 2024	SELL Open market or private sale	$12,917 $1.25 p/Share	10,334 Reduced 11.26%	81,439 Common Stock
Nov 06 2024	SELL Payment of exercise price or tax liability	$859 $0.86 p/Share	999 Reduced 1.08%	91,773 Common Stock
Nov 01 2024	SELL Payment of exercise price or tax liability	$916 $0.8 p/Share	1,146 Reduced 1.22%	92,772 Common Stock
Aug 06 2024	SELL Payment of exercise price or tax liability	$869 $0.87 p/Share	999 Reduced 1.05%	93,918 Common Stock
Aug 01 2024	SELL Payment of exercise price or tax liability	$1,077 $0.94 p/Share	1,146 Reduced 1.19%	94,917 Common Stock
Jun 03 2024	SELL Open market or private sale	$20,356 $1.39 p/Share	14,645 Reduced 13.23%	96,063 Common Stock
May 06 2024	SELL Payment of exercise price or tax liability	$1,748 $1.75 p/Share	999 Reduced 0.89%	110,708 Common Stock
May 01 2024	SELL Payment of exercise price or tax liability	$2,028 $1.77 p/Share	1,146 Reduced 1.02%	111,707 Common Stock
Feb 06 2024	SELL Payment of exercise price or tax liability	$2,737 $2.32 p/Share	1,180 Reduced 1.03%	112,853 Common Stock
Jan 29 2024	BUY Grant, award, or other acquisition	-	62,500 Added 35.4%	114,033 Common Stock
Nov 06 2023	SELL Payment of exercise price or tax liability	$1,818 $1.82 p/Share	999 Reduced 1.9%	51,533 Common Stock
Aug 07 2023	SELL Payment of exercise price or tax liability	$2,667 $2.67 p/Share	999 Reduced 1.87%	52,532 Common Stock
May 08 2023	SELL Payment of exercise price or tax liability	$4,011 $4.14 p/Share	969 Reduced 1.78%	53,531 Common Stock
Feb 06 2023	BUY Grant, award, or other acquisition	-	54,500 Added 50.0%	54,500 Common Stock

Also insider at

APRE

Aprea Therapeutics, Inc. Healthcare

SVP, Chief Medical Officer

ECA

Eyal C. Attar

CHIEF MEDICAL OFFICER

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VOR shares.

Notify only if

Value

Insider Trading

Get notified when an Vor Biopharma Inc. insider buys or sells VOR shares.

Notify only if

Operation

Value

Type

News

Receive news related to Vor Biopharma Inc.

Track Activities on VOR

Account